Eli Lilly said Wednesday that its experimental drug solanezumab failed to improve cognition of patients with mild Alzheimer's disease in a large phase III clinical trial.

If you liked this article you might like

Nevada Senate Passes Bill to Force Diabetes Drug Manufacturers to Disclose Pricing Practices
Eli Lilly Stock Faces Uncertainty, Bernstein Says
Here Are Some of Congress' Favorite Stocks
Good, the Bad and the Ugly; What Troubles Me: Doug Kass' Views